URGN EBITDA | UroGen Pharma Ltd.

UroGen Pharma Ltd. (URGN) EBITDA

2026-06-30: Basis Reported; EBITDA $211,000.00; Operating income (m); Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA -$20.19M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$19.04M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$27.29M; Operating income (m); Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2016-12-31 to 2026-06-30
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	$211,000.00	(m)	(m)	$72.46M	0.29%	$60.00K*	-$33.01M*	(m)	$17.34M	$48.44M	$5.63M
2026-03-31	Reported	-$20.19M	(m)	(m)	$50.96M	-39.62%	$54.00K	-$45.32M	(m)	$15.60M	$51.49M	-$4.77M
2025-12-31	Reported	-$19.04M	(m)	(m)	$37.84M	-50.32%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$27.29M	(m)	(m)	$27.48M	-99.29%	$87.00K*	-$42.27M*	(m)	$14.01M	$37.58M	-$1.05M
2025-06-30	Reported	-$41.35M	(m)	(m)	$24.22M	-170.75%	$141.00K*	-$39.83M*	(m)	$18.91M	$43.20M	$1.01M
2025-03-31	Reported	-$36.84M	(m)	(m)	$20.25M	-181.90%	$44.00K	-$42.02M	(m)	$19.87M	$34.97M	$392.00K
2024-12-31	Reported	-$27.59M	(m)	(m)	$24.57M	-112.31%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$17.45M	(m)	(m)	$25.2M	-69.22%	$96.00K*	-$27.66M*	(m)	$11.36M	$28.94M	$91.00K
2024-06-30	Reported	-$25.74M	(m)	(m)	$21.85M	-117.81%	$84.00K*	-$23.75M*	(m)	$15.40M	$30.06M	$38.00K
2024-03-31	Reported	-$25.62M	(m)	(m)	$18.78M	-136.40%	$0.00	-$31.73M	(m)	$15.49M	$27.30M	$54.00K
2023-12-31	Reported	-$14.42M	(m)	(m)	$23.53M	-61.28%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$13.3M	(m)	(m)	$20.85M	-63.78%	$100.00K*	-$17.30M*	(m)	$10.23M	$21.75M	-$9.00K
2023-06-30	Reported	-$15.18M	(m)	(m)	$21.14M	-71.82%	$15.00K*	-$20.27M*	(m)	$11.58M	$22.49M	$54.00K
2023-03-31	Reported	-$21.83M	(m)	(m)	$17.19M	-126.97%	$23.00K	-$25.81M	(m)	$12.50M	$24.47M	$21.00K
2022-12-31	Reported	-$20.05M	(m)	(m)	$18.09M	-110.80%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$17.89M	(m)	(m)	$16.1M	-111.12%	$153.00K*	-$17.61M*	(m)	$13.09M	$19.07M	$709.00K
2022-06-30	Reported	-$18.52M	(m)	(m)	$16.6M	-111.51%	$63.00K*	-$24.20M*	(m)	$12.64M	$20.83M	$32.00K
2022-03-31	Reported	-$21.74M	(m)	(m)	$13.56M	-160.29%	$25.00K	-$24.00M	(m)	$12.70M	$21.30M	$325.00K
2021-12-31	Reported	-$19.7M	(m)	(m)	$16.17M	-121.81%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$23.24M	(m)	(m)	$11.35M	-204.74%	$194.00K*	-$18.48M*	(m)	$11.92M	$21.62M	$0.00
2021-06-30	Reported	-$22.62M	(m)	(m)	$13.03M	-173.60%	$69.00K*	-$18.95M*	(m)	$12.12M	$22.30M	$312.00K
2021-03-31	Reported	-$25.92M	(m)	(m)	$7.49M	-346.33%	$287.00K	-$27.40M	(m)	$10.51M	$22.19M	$0.00
2020-12-31	Reported	-$27.13M	(m)	(m)	$7.97M	-340.61%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$29.02M	(m)	(m)	$3.46M	-838.60%	$660.00K*	-$25.08M*	(m)	$10.21M	$22.07M	$0.00
2020-06-30	Reported	-$31.7M	(m)	(m)	$372,000.00	-8521.51%	$287.00K*	-$23.93M*	(m)	$8.11M	$24.02M	(m)
2020-03-31	Reported	-$38.46M	(m)	(m)	(m)	(m)	$96.00K	-$35.63M	(m)	$16.59M	$21.97M	(m)
2019-12-31	Reported	-$39.74M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$23.35M	(m)	(m)	(m)	(m)	$49.00K*	-$12.53M*	(m)	$9.48M	$13.97M	(m)
2019-06-30	Reported	-$23.65M	(m)	(m)	$18,000.00	-131405.56%	$40.00K*	-$14.55M*	(m)	$10.00M	$13.78M	(m)
2019-03-31	Reported	-$22.33M	(m)	(m)	(m)	(m)	$44.00K	-$17.93M	(m)	$9.73M	$12.71M	(m)
2018-12-31	Reported	-$23.82M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$20.99M	(m)	(m)	$283,000.00	-7416.61%	$332.00K*	-$9.28M*	(m)	$9.57M	(m)	(m)
2018-06-30	Reported	-$18.39M	(m)	(m)	$364,000.00	-5051.23%	$132.00K*	-$8.15M*	(m)	$8.27M	(m)	(m)
2018-03-31	Reported	-$13.44M	(m)	(m)	$481,000.00	-2794.18%	$72.00K	-$9.62M	(m)	$7.62M	(m)	(m)
2017-12-31	Reported	(m)	-$10.16M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	(m)	-$303.00K	(m)	(m)	(m)	$20.00K*	$2.60M*	(m)	$5.62M	(m)	(m)
2017-06-30	Reported	(m)	-$5.95M	(m)	(m)	(m)	$20.00K*	-$3.46M*	(m)	$3.65M	(m)	(m)
2017-03-31	Reported	(m)	-$3.54M	(m)	(m)	(m)	$78.00K	-$2.75M	(m)	$2.66M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$124.56M	(m)	(m)	$109.79M	-113.45%	$289.00K	-$162.44M	(m)	$67.11M	$155.10M	$78.00K
2024-12-31	Reported	-$96.45M	(m)	(m)	$90.4M	-106.70%	$295.00K	-$96.77M	(m)	$57.15M	$121.15M	$2.83M
2023-12-31	Reported	-$64.73M	(m)	(m)	$82.71M	-78.26%	$194.00K	-$76.38M	(m)	$45.61M	$93.27M	$3.92M
2022-12-31	Reported	-$78.12M	(m)	(m)	$64.36M	-121.38%	$254.00K	-$87.56M	(m)	$52.91M	$82.84M	$1.75M
2021-12-31	Reported	-$91.46M	(m)	(m)	$48.04M	-190.38%	$752.00K	-$84.89M	(m)	$47.64M	$87.53M	$1.45M
2020-12-31	Reported	-$126.32M	(m)	(m)	$11.8M	-1070.62%	$1.22M	-$105.89M	(m)	$47.31M	$90.22M	$3.37M
2020-09-30	Rolling	(m)	-$139.32M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$133.65M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$125.61M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$109.18M	(m)	(m)	$18,000.00	-606544.44%	$325.00K	-$71.02M	(m)	$49.30M	$60.20M	(m)
2019-12-31	Rolling	(m)	-$109.48M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$93.66M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$91.29M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$85.97M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$76.78M	(m)	(m)	$1.13M	-6806.74%	$560.00K	-$37.33M	(m)	$36.93M	(m)	$125.00K
2018-12-31	Rolling	(m)	-$77.18M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$63.32M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$42.53M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$30.05M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$19.75M	(m)	(m)	$8.16M	-242.09%	$271.00K	-$9.57M	(m)	$18.70M	(m)	$19.00K
2017-12-31	Rolling	(m)	-$19.95M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	$998,000.00	(m)	(m)	$17.53M	5.69%	$695.00K	$4.19M	(m)	(m)	(m)	(m)
2015-12-31	Reported	(m)	-$12.41M	(m)	(m)	(m)	$301.00K	-$7.17M	(m)	(m)	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Nuvation Bio Inc. (NUVB)	United States	$2.007B	-13.12
NEKTAR THERAPEUTICS (NKTR)	United States	$2.026B	-9.05
PERRIGO Co plc (PRGO)	Ireland	$2.038B	-0.79
Biohaven Ltd. (BHVN)	United States	$1.990B	-3.83
Generate Biomedicines, Inc. (GENB)	United States	$2.052B
AGIOS PHARMACEUTICALS, INC. (AGIO)	United States	$1.962B	-5.38
Sarepta Therapeutics, Inc. (SRPT)	United States	$1.941B	-13.89
Trevi Therapeutics, Inc. (TRVI)	United States	$2.091B	-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)	United States	$2.105B	-35.55
Braveheart Bio, Inc. (BRVE)	United States	$2.106B